ES2262346T3 - Celulas, procedimientos de cultivo y su uso en terapia de trasplantes autologos. - Google Patents
Celulas, procedimientos de cultivo y su uso en terapia de trasplantes autologos.Info
- Publication number
- ES2262346T3 ES2262346T3 ES99954269T ES99954269T ES2262346T3 ES 2262346 T3 ES2262346 T3 ES 2262346T3 ES 99954269 T ES99954269 T ES 99954269T ES 99954269 T ES99954269 T ES 99954269T ES 2262346 T3 ES2262346 T3 ES 2262346T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- use according
- host
- cell
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 62
- 210000004027 cell Anatomy 0.000 claims abstract description 249
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 77
- 201000010099 disease Diseases 0.000 claims abstract description 54
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 28
- 208000035475 disorder Diseases 0.000 claims abstract description 22
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 20
- 230000001413 cellular effect Effects 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 238000002054 transplantation Methods 0.000 claims description 16
- 238000007710 freezing Methods 0.000 claims description 13
- 230000008014 freezing Effects 0.000 claims description 13
- 210000000987 immune system Anatomy 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 208000032839 leukemia Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000003860 storage Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 13
- 206010025323 Lymphomas Diseases 0.000 description 12
- 238000005138 cryopreservation Methods 0.000 description 12
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 12
- 238000005070 sampling Methods 0.000 description 12
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 239000001307 helium Substances 0.000 description 9
- 229910052734 helium Inorganic materials 0.000 description 9
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 102000004067 Osteocalcin Human genes 0.000 description 7
- 108090000573 Osteocalcin Proteins 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- -1 and serum Substances 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 238000012754 cardiac puncture Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000003140 lateral ventricle Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108050004784 Huntingtin Proteins 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
- C12N2533/18—Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9825096 | 1998-11-16 | ||
| GB9825096A GB2343679A (en) | 1998-11-16 | 1998-11-16 | Autologous transplantation and method for making cells dormant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2262346T3 true ES2262346T3 (es) | 2006-11-16 |
Family
ID=10842531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99954269T Expired - Lifetime ES2262346T3 (es) | 1998-11-16 | 1999-11-16 | Celulas, procedimientos de cultivo y su uso en terapia de trasplantes autologos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060246042A1 (OSRAM) |
| EP (1) | EP1131408B1 (OSRAM) |
| JP (1) | JP2002530293A (OSRAM) |
| AT (1) | ATE321843T1 (OSRAM) |
| AU (1) | AU775597B2 (OSRAM) |
| CY (1) | CY1105439T1 (OSRAM) |
| DE (1) | DE69930660T2 (OSRAM) |
| DK (1) | DK1131408T3 (OSRAM) |
| ES (1) | ES2262346T3 (OSRAM) |
| GB (1) | GB2343679A (OSRAM) |
| PT (1) | PT1131408E (OSRAM) |
| WO (1) | WO2000029551A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0322806D0 (en) | 2003-09-30 | 2003-10-29 | Lifeforce Group Plc | Cell bank for contingent autologous leukocyte transplantation |
| EP1711214A1 (en) | 2004-02-02 | 2006-10-18 | Interface Multigrad Technology (IMT) Ltd. | Device for directional cooling of biological matter |
| JP4777908B2 (ja) | 2004-02-02 | 2011-09-21 | コア・ダイナミクス・リミテッド | 生物学的材料ならびに生物学的材料の保存のための方法および溶液 |
| ATE460947T1 (de) | 2004-06-07 | 2010-04-15 | Core Dynamics Ltd | Verfahren zur sterilisation von biologischen präparaten |
| US8037696B2 (en) | 2004-08-12 | 2011-10-18 | Core Dynamics Limited | Method and apparatus for freezing or thawing of a biological material |
| US8198085B2 (en) | 2005-08-03 | 2012-06-12 | Core Dynamics Limited | Somatic cells for use in cell therapy |
| DE102007004855B4 (de) * | 2007-01-31 | 2014-03-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Vorrichtung und Verfahren zur Deposition von biologischem Material in einem Zielsubstrat |
| US20120070450A1 (en) * | 2009-03-24 | 2012-03-22 | Riken | Leukemia stem cell markers |
| EP2943206A4 (en) * | 2013-01-12 | 2017-01-04 | Cesca Therapeutics Inc. | Rapid infusion of autologous bone marrow derived stem cells |
| ES2729640T3 (es) * | 2013-10-24 | 2019-11-05 | Neuroplast Beheer B V | Procedimiento de reducción de la actividad inflamatoria de un trasplante de células madre y usos del mismo |
| CN105219709A (zh) * | 2015-09-23 | 2016-01-06 | 上海吉泉生物技术有限公司 | 单采法建立免疫细胞库及应用 |
| CL2016000753A1 (es) * | 2016-03-31 | 2017-11-10 | Fund Ciencia Para La Vida | Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+. |
| JP6401818B2 (ja) * | 2016-04-27 | 2018-10-10 | 株式会社金太郎ＣｅｌｌｓＰｏｗｅｒ | 活性化幹細胞製造方法 |
| DE102021116694B4 (de) * | 2021-06-29 | 2023-03-09 | Promocell Gmbh | Wässrige Lösung zur Zellkonservierung |
| CN114984048A (zh) * | 2022-06-16 | 2022-09-02 | 浙江百越生物技术有限公司 | 一种预防与治疗老年人行动迟缓的细胞疗法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
| JPH04282301A (ja) * | 1991-03-08 | 1992-10-07 | Kachiku Jiyuseiran Ishiyoku Gijutsu Kenkyu Kumiai | 生物試料の急速凍結方法 |
| US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| AU6167394A (en) * | 1993-01-27 | 1994-08-15 | Hemosol Inc. | Selective cell proliferation |
| AU8078894A (en) * | 1993-10-08 | 1995-05-04 | Cellpro Ii | Methods for collection and cryopreservation of human granulocytes |
| US5866332A (en) * | 1994-02-02 | 1999-02-02 | Incyte Pharmaceuticals, Inc. | Human myeloid terminal differentiation response gene |
| EP0668013B1 (en) * | 1994-02-22 | 2005-04-20 | Nippon Telegraph And Telephone Corporation | Freeze-dried blood cells, stem cells and platelets and manufacturing method for the same |
| US5704889A (en) * | 1995-04-14 | 1998-01-06 | Cobe Laboratories, Inc. | Spillover collection of sparse components such as mononuclear cells in a centrifuge apparatus |
| US5865784A (en) * | 1995-06-07 | 1999-02-02 | Alliance Pharmaceutical Corp. | Method of hemodilution facilitated by monitoring oxygenation status |
| US5922597A (en) * | 1995-11-14 | 1999-07-13 | Regents Of The University Of Minnesota | Ex vivo culture of stem cells |
| JP2002515756A (ja) * | 1997-01-31 | 2002-05-28 | ヘモソル インク． | 選択されたリンパ球の生産方法 |
| AU6346898A (en) * | 1997-03-06 | 1998-09-22 | University Of Massachusetts | Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters |
-
1998
- 1998-11-16 GB GB9825096A patent/GB2343679A/en not_active Withdrawn
-
1999
- 1999-11-16 WO PCT/GB1999/003813 patent/WO2000029551A2/en not_active Ceased
- 1999-11-16 JP JP2000582535A patent/JP2002530293A/ja active Pending
- 1999-11-16 AT AT99954269T patent/ATE321843T1/de not_active IP Right Cessation
- 1999-11-16 ES ES99954269T patent/ES2262346T3/es not_active Expired - Lifetime
- 1999-11-16 PT PT99954269T patent/PT1131408E/pt unknown
- 1999-11-16 AU AU10680/00A patent/AU775597B2/en not_active Ceased
- 1999-11-16 EP EP99954269A patent/EP1131408B1/en not_active Revoked
- 1999-11-16 DE DE69930660T patent/DE69930660T2/de not_active Expired - Lifetime
- 1999-11-16 DK DK99954269T patent/DK1131408T3/da active
-
2006
- 2006-04-10 US US11/400,767 patent/US20060246042A1/en not_active Abandoned
- 2006-06-26 CY CY20061100868T patent/CY1105439T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2343679A (en) | 2000-05-17 |
| CY1105439T1 (el) | 2010-04-28 |
| DE69930660D1 (de) | 2006-05-18 |
| EP1131408A2 (en) | 2001-09-12 |
| PT1131408E (pt) | 2006-08-31 |
| DE69930660T2 (de) | 2007-04-05 |
| ATE321843T1 (de) | 2006-04-15 |
| AU775597B2 (en) | 2004-08-05 |
| US20060246042A1 (en) | 2006-11-02 |
| AU1068000A (en) | 2000-06-05 |
| WO2000029551B1 (en) | 2001-01-11 |
| DK1131408T3 (da) | 2006-08-07 |
| EP1131408B1 (en) | 2006-03-29 |
| WO2000029551A2 (en) | 2000-05-25 |
| JP2002530293A (ja) | 2002-09-17 |
| GB9825096D0 (en) | 1999-01-13 |
| WO2000029551A3 (en) | 2000-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Little et al. | History of haematopoietic stem-cell transplantation | |
| Nicolay et al. | Mesenchymal stem cells–A new hope for radiotherapy-induced tissue damage? | |
| Arora et al. | Banking stem cells from human exfoliated deciduous teeth (SHED): saving for the future | |
| KR101644984B1 (ko) | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물 | |
| Hellström et al. | Colony inhibition of fibroblasts from chimeric dogs mediated by the dogs' own lymphocytes and specifically abrogated by their serum | |
| AU775597B2 (en) | Cells, culture methods and their uses | |
| KR20140035102A (ko) | 100㎖ 이하 말초혈액으로부터 ｎｋ세포의 대량 증식 방법 | |
| ES2660577T3 (es) | Células que expresan características y propiedades citolíticas de Th1 | |
| Wood et al. | Specific tolerance to neural allografts induced with an antibody to the interleukin 2 receptor. | |
| Azuma et al. | Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease. | |
| CN109985064B (zh) | 间充质干细胞分泌提取物的用途、间充质干细胞分泌提取物及其制备方法 | |
| CN117980470A (zh) | 治疗性nk细胞群 | |
| WO2001088099A1 (en) | Cells, culture methods and their uses | |
| ES2537755T3 (es) | Citoblastos atrapados y usos de los mismos | |
| RU2462511C2 (ru) | Способ пролиферации клеток lak | |
| KR20190093500A (ko) | Cd56+ 자연살해세포를 포함하는 항암용 조성물 | |
| Mohammadi et al. | Human peripheral blood derived hematopoietic stem cell: history, the isolation methods and investigation of different parameters effects on their differentiation to the body cells | |
| Hu et al. | Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice | |
| Blume et al. | A History of Allogeneic and Autologous Hematopoietic Cell Transplantation | |
| Wang et al. | Peptide Tk-PQ induces immunosuppression in skin allogeneic transplantation via increasing Foxp3+ Treg and impeding nuclear translocation of NF-κB | |
| HK1209280A1 (en) | Protocol and media for storage and transport of nk-92 cell line | |
| JP2016533720A (ja) | Ｎｋ−９２細胞株を保存および輸送するためのプロトコールおよび培地 | |
| JPS5821621A (ja) | ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤 | |
| WO2018195070A1 (en) | Gut-protective effect of rig-i/mavs and sting activation | |
| Pierpaoli | Growth of transplantable melanoma and leukaemia and prevention of virus-induced leukaemia in long lived radiation chimeras constructed with unmanipulated bone marrow |